{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:03:12Z","timestamp":1767171792374,"version":"build-2238731810"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Genetic variations in the inflammatory\n                      <jats:italic>Caspase-1<\/jats:italic>\n                      gene have been shown associated with cognitive function in elderly individuals and in predisposition to Alzheimer\u2019s disease (AD), but its detailed mechanism before the typical AD onset was still unclear. Our current study evaluated the impact of\n                      <jats:italic>Caspase-1<\/jats:italic>\n                      common variant rs554344 on the pathological processes of brain amyloidosis, tauopathy, and neurodegeneration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data used in our study were obtained from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) cohort. We examined the relationship between\n                      <jats:italic>Caspase-1<\/jats:italic>\n                      rs554344 allele carrier status with AD-related cerebrospinal fluid (CSF), PET, and MRI measures at baseline by using a multiple linear regression model. We also analyzed the longitudinal effects of this variant on the change rates of CSF biomarkers and imaging data using a mixed effect model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that\n                      <jats:italic>Caspase-1<\/jats:italic>\n                      variant was significantly associated with FDG PET levels and CSF t-tau levels at baseline in total non-demented elderly group, and especially in mild cognitive impairment (MCI) subgroup. In addition, this variant was also detected associated with CSF p-tau levels in MCI subgroup. The mediation analysis showed that CSF p-tau partially mediated the association between\n                      <jats:italic>Caspase-1<\/jats:italic>\n                      variant and CSF t-tau levels, accounting for 80% of the total effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study indicated a potential role of\n                      <jats:italic>Caspase-1<\/jats:italic>\n                      variant in influencing cognitive function might through changing tau related-neurodegeneration process.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-02582-9","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T04:04:01Z","timestamp":1644984241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort"],"prefix":"10.1186","volume":"22","author":[{"given":"Yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Shan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuo-Teng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"6","key":"2582_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358\u201372. https:\/\/doi.org\/10.1038\/nrn3880.","journal-title":"Nat Rev Neurosci"},{"key":"2582_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-med-050715-104343","volume":"69","author":"LI Labzin","year":"2018","unstructured":"Labzin LI, Heneka MT, Latz E. Innate immunity and Neurodegeneration. Annu Rev Med. 2018;69:437\u201349. https:\/\/doi.org\/10.1146\/annurev-med-050715-104343.","journal-title":"Annu Rev Med"},{"issue":"7434","key":"2582_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493(7434):674\u20138. https:\/\/doi.org\/10.1038\/nature11729.","journal-title":"Nature."},{"issue":"7784","key":"2582_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669\u201373. https:\/\/doi.org\/10.1038\/s41586-019-1769-z.","journal-title":"Nature."},{"key":"2582_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.arr.2013.12.007","volume":"15","author":"L Liu","year":"2014","unstructured":"Liu L, Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res Rev. 2014;15:6\u201315. https:\/\/doi.org\/10.1016\/j.arr.2013.12.007.","journal-title":"Ageing Res Rev"},{"key":"2582_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-016-0088-1","volume":"11","author":"M Saresella","year":"2016","unstructured":"Saresella M, La Rosa F, Piancone F, Zoppis M, Marventano I, Calabrese E, et al. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol Neurodegener. 2016;11:23. https:\/\/doi.org\/10.1186\/s13024-016-0088-1.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"2582_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s12035-013-8475-x","volume":"48","author":"MS Tan","year":"2013","unstructured":"Tan MS, Yu JT, Jiang T, Zhu XC, Tan L. The NLRP3 inflammasome in Alzheimer's disease. Mol Neurobiol. 2013;48(3):875\u201382. https:\/\/doi.org\/10.1007\/s12035-013-8475-x.","journal-title":"Mol Neurobiol"},{"issue":"14","key":"2582_CR8","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720\u201332. https:\/\/doi.org\/10.1182\/blood-2010-07-273417.","journal-title":"Blood."},{"issue":"7610","key":"2582_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature18590","volume":"535","author":"J Ding","year":"2016","unstructured":"Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016;535(7610):111\u20136. https:\/\/doi.org\/10.1038\/nature18590.","journal-title":"Nature."},{"issue":"Pt 4","key":"2582_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/brain\/awn023","volume":"131","author":"S Trompet","year":"2008","unstructured":"Trompet S, de Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, et al. Genetic variation in the interleukin-1 beta-converting enzyme associates with cognitive function. The PROSPER study. Brain. 2008;131(Pt 4):1069\u201377. https:\/\/doi.org\/10.1093\/brain\/awn023.","journal-title":"Brain"},{"issue":"8","key":"2582_CR11","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1007\/s00415-011-5935-y","volume":"258","author":"A Pozueta","year":"2011","unstructured":"Pozueta A, V\u00e1zquez-Higuera JL, S\u00e1nchez-Juan P, Rodr\u00edguez-Rodr\u00edguez E, S\u00e1nchez-Quintana C, Mateo I, et al. Genetic variation in caspase-1 as predictor of accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neurol. 2011;258(8):1538\u20139. https:\/\/doi.org\/10.1007\/s00415-011-5935-y.","journal-title":"J Neurol"},{"issue":"3","key":"2582_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dementia"},{"issue":"4","key":"2582_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2582_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","volume":"1","author":"SG Mueller","year":"2005","unstructured":"Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimers Dementia. 2005;1(1):55\u201366. https:\/\/doi.org\/10.1016\/j.jalz.2005.06.003.","journal-title":"Alzheimers Dementia"},{"issue":"2","key":"2582_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","volume":"51","author":"A Olsson","year":"2005","unstructured":"Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336\u201345. https:\/\/doi.org\/10.1373\/clinchem.2004.039347.","journal-title":"Clin Chem"},{"issue":"3","key":"2582_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3233\/jad-180431","volume":"65","author":"MS Tan","year":"2018","unstructured":"Tan MS, Wang P, Ma FC, Li JQ, Tan CC, Yu JT, et al. Common variant in PLD3 influencing cerebrospinal fluid Total tau levels and hippocampal volumes in mild cognitive impairment patients from the ADNI cohort. J Alzheimers Dis. 2018;65(3):871\u20136. https:\/\/doi.org\/10.3233\/jad-180431.","journal-title":"J Alzheimers Dis"},{"key":"2582_CR17","doi-asserted-by":"publisher","first-page":"1:15","DOI":"10.1186\/s13195-020-00755-7","volume":"13","author":"MS Tan","year":"2021","unstructured":"Tan MS, Yang YX, Xu W, Wang HF, Tan L, Zuo CT, et al. Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. Alzheimers Res Ther. 2021;13:1:15. https:\/\/doi.org\/10.1186\/s13195-020-00755-7.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"2582_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jalz.2019.05.006","volume":"15","author":"JT Yu","year":"2019","unstructured":"Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: a longitudinal study. Alzheimers Dementia. 2019;15(9):1208\u201317. https:\/\/doi.org\/10.1016\/j.jalz.2019.05.006.","journal-title":"Alzheimers Dementia"},{"issue":"4","key":"2582_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685\u201391. https:\/\/doi.org\/10.1002\/jmri.21049.","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"2582_CR20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1037\/\/0022-3514.51.6.1173","volume":"51","author":"RM Baron","year":"1986","unstructured":"Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173\u201382. https:\/\/doi.org\/10.1037\/\/0022-3514.51.6.1173.","journal-title":"J Pers Soc Psychol"},{"issue":"8","key":"2582_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ni.1636","volume":"9","author":"A Halle","year":"2008","unstructured":"Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857\u201365. https:\/\/doi.org\/10.1038\/ni.1636.","journal-title":"Nat Immunol"},{"issue":"8","key":"2582_CR22","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1038\/cddis.2014.348","volume":"5","author":"MS Tan","year":"2014","unstructured":"Tan MS, Tan L, Jiang T, Zhu XC, Wang HF, Jia CD, et al. Amyloid-\u03b2 induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease. Cell Death Dis. 2014;5(8):e1382. https:\/\/doi.org\/10.1038\/cddis.2014.348.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2582_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/jnr.24130","volume":"96","author":"L \u00c1lvarez-Arellano","year":"2018","unstructured":"\u00c1lvarez-Arellano L, Pedraza-Escalona M, Blanco-Ayala T, Camacho-Concha N, Cort\u00e9s-Mendoza J, P\u00e9rez-Mart\u00ednez L, et al. Autophagy impairment by caspase-1-dependent inflammation mediates memory loss in response to \u03b2-amyloid peptide accumulation. J Neurosci Res. 2018;96(2):234\u201346. https:\/\/doi.org\/10.1002\/jnr.24130.","journal-title":"J Neurosci Res"},{"key":"2582_CR24","doi-asserted-by":"publisher","first-page":"1:4571","DOI":"10.1038\/s41467-020-18405-9","volume":"11","author":"J Flores","year":"2020","unstructured":"Flores J, No\u00ebl A, Foveau B, Beauchet O, LeBlanc AC. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun. 2020;11:1:4571. https:\/\/doi.org\/10.1038\/s41467-020-18405-9.","journal-title":"Nat Commun"},{"issue":"3","key":"2582_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/1567205014666170417111859","volume":"15","author":"Y Gao","year":"2018","unstructured":"Gao Y, Tan L, Yu JT, Tan L. Tau in Alzheimer's disease: mechanisms and therapeutic strategies. Curr Alzheimer Res. 2018;15(3):283\u2013300. https:\/\/doi.org\/10.2174\/1567205014666170417111859.","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"2582_CR26","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/01.wnl.0000063311.58879.01","volume":"60","author":"P Giannakopoulos","year":"2003","unstructured":"Giannakopoulos P, Herrmann FR, Bussi\u00e8re T, Bouras C, K\u00f6vari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60(9):1495\u2013500. https:\/\/doi.org\/10.1212\/01.wnl.0000063311.58879.01.","journal-title":"Neurology."},{"key":"2582_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.11.010","volume":"326","author":"BS Thawkar","year":"2019","unstructured":"Thawkar BS, Kaur G. Inhibitors of NF-\u03baB and P2X7\/NLRP3\/Caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer's disease. J Neuroimmunol. 2019;326:62\u201374. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.11.010.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"2582_CR28","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1038\/s41467-018-06449-x","volume":"9","author":"J Flores","year":"2018","unstructured":"Flores J, No\u00ebl A, Foveau B, Lynham J, Lecrux C, LeBlanc AC. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model. Nat Commun. 2018;9(1):3916. https:\/\/doi.org\/10.1038\/s41467-018-06449-x.","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1186\/s12883-022-02616-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02582-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02582-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02582-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T02:05:53Z","timestamp":1647828353000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02582-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2582"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02582-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12883-022-02616-2","URL":"https:\/\/doi.org\/10.1186\/s12883-022-02616-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used in our study were obtained from the official ADNI website, its data-sharing policy making us available to all data. Our experimental protocols were approved by the Institutional Review Board of Qingdao Municipal Hospital.The ADNI study was approved by institutional review boards of all participating institutions, and written informed consent was obtained from all participants or their guardians according to the Declaration of Helsinki (consent for research).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}